List view / Grid view
From precision proteomics to AI-powered immune profiling, next-generation laboratory technologies are changing how new therapies are discovered and developed. Here are four innovations set to shape the lab of the future - and the future of drug discovery.
Scientists from Nagoya University have developed a fast and safe method to create lung cells from skin-like fibroblasts - without using stem cells. This technique could allow for new regenerative therapies for diseases like chronic obstructive pulmonary disease (COPD).
Researchers at the University of Illinois have achieved the first successful metabolic labelling of platelets, a key step toward using them in targeted drug delivery. The technique could enable short-lived, precision therapies for cancer, immune conditions, and clotting disorders.
The researchers argue hepatocytes are susceptible to SARS-CoV-2 pseudovirus infection and propose that metformin could be a therapeutic option to attenuate SARS-CoV-2 infection in patients with fatty liver.
Combining AI with cutting-edge flow cytometry and massive sequencing technologies, researchers describe CAR T cell characteristics that determine their therapeutic capacity for the first time.
Swedish researchers have discovered that by measuring immune cells in the cerebrospinal fluid when diagnosing ALS, it is possible to predict how fast the disease may progress.
Researchers have developed a novel label-free method named tomographic phase microscopy in flow cytometry for measuring intracellular lipid droplets in 3D.
Dr Greg Neely, University of Sydney, explains how he and his team used pooled whole genome CRISPR activation screening to identify LRRC15 as a SARS-CoV-2 spike-interacting protein.
Dr Alasdair Gunn and Natalie Bath from Adaptimmune explain how flow cytometry provides a useful tool for the development of immuno-oncology therapies. They also explore how they use this method for translational research of the company’s SPEAR T-cell products.
With a range of tools available to scientists in the field of therapeutic discovery and development, flow cytometry presents an advantageous method to sort cells based on subtle differences. To find out more, Drug Target Review’s Victoria Rees spoke with Dr Peter O’Toole, Head of Imaging and Cytometry and Dr…
This ebook includes articles on flow cytometry in drug discovery and how it is applied to leishmaniasis research. Also included is a piece on how flow cytometry is being used to support the translational research of immuno-oncology therapies.
This issue includes articles that discuss the development of long-term 3D tissue cultures from human biopsy samples, the application of flow cytometry in drug discovery and automation for upstream processing in a biologics manufacturing environment. Also included are features on informatics, proteomics and CRISPR.
Researchers have found that the PI3K signalling pathway could be targeted to prevent liptoxicity and combat obesity.
According to the study, the transcription factor IRF4 drives T cell differentiation and immunosuppression in multiple human cancers.
Researchers used flow cytometry to characterise which types of T cells are involved in the immune response to COVID-19 and what they target.
